Exploring the Complex Interplay of SGLT2 Inhibitors, Iron, and Hemoglobin

Exploring the complex interplay between SGLT2 inhibitors, hepsidin, ferritin, and cytosolic iron levels in CKD and heart failure patients, and the potential alterations in iron levels following medication initiation. Discussions on the consequences of reduced ferritin levels and the difficulties in accurately measuring cytosolic iron content.